BioVaxys Technology Corp. BVAXF
0.09 USD 0.00 (+0.00%)
At closeNov 2, 2026, 4:00 PM EST
0.0677 Day range 0.0677
0.0102 52-week range 0.208
- YTD
- -46.84%
- 1 year
- -55.47%
- Market cap
- 3.66M
- EPS (ttm)
- -0.15
- YTD return
- -46.84%
- 1-year return
- -55.47%
- Volume
- 150
- Avg volume
- 21.18K
- Open
- 0.0677
- Previous close
- 0.09
- Day's range
- 0.0677 – 0.0677
- 52-week range
- 0.0102 – 0.208
2Y -0.4500 (-83.33%)
News
BioVaxys Technology Corp. to Present at the Moody Capital Solutions 2026 Disruptive Growth & Life Sciences Conference 
BioVaxys Presents Further Validation of the Robust Immune Response from a Combination of MVP-S with Checkpoint Inhibitors and Low-Dose Cyclophosphamide in Ovarian Cancer 
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update 
BioVaxys Announces Phase I/II PESCO Trial Abstract Accepted for Presentation at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting 
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update 
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update 
BioVaxys Technology Corp. Provides Bi-Weekly MCTO Status Update 
BioVaxys Announces Application for Management Cease Trade Order 
BioVaxys Reports Positive Phase 2 Data for Maveropepimut (MVP-S) + Pembrolizumab and Low-Dose Cyclophosphamide in Metastatic Bladder Cancer 
BioVaxys Reports Positive Clinical Study Results from Phase 1B/2 PESCO Trial of MVP-S with Pembrolizumab (Keytruda (TM)) and Low-Dose Cyclophosphamide for Patients with Recurrent Epithelial Ovarian Cancer (EOC)
Your note
Sign in to keep a note on BVAXF — it syncs with the Stock Master app.